|
Lovastatin is a lipid lowering agent for the treatment of hypercholesterolemia and belongs to a new class of pharmacologic compounds called the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors. By competitively inhibiting HMG CoA reductase, lovastatin disrupts the biosynthesis of cholesterol in hepatic and peripheral cells and increases the synthesis of high-density-lipoprotein HDL) receptors. Following oral administration, the lactone ring of lovastatin is hydrolysed to the active inhibitor of HMG CoA reductase, lovastatin acid. Lovastatin is known to have poor oral absorption and wide individual variation. In this study, bioequivalence test of two lovastatin formulations, the test drug (Lovaload^{TM}, Chong Kun Dang Pharmaceutical Co.) and the reference drug (Mevacor^{TM}, Chung Wae Pharmaceutical Co.) were conducted according to the guidelines of Korea Food and Drug Administration (KFDA). A total of 18 healthy male volunteers, 31.90pm3.60 years old and 72.17;7.88 kg of body weight in average, were evaluated in a randomized crossover manner with a 2-week washout period. Concentrations of lovastatin acid in plasma were measured upto 12 hours following a single oral administration of eight tablets (20 mg of lovastatin per tablet) by high-performance liquid chromatography with UV detection at 238 nm. The area under the concentration-vs-time curve from 0 to 12 hours (AUC_{0-12h}) was calculated by the trapezoidal summation method. The statistical analysis showed that there are no significant differences in AUC_{0-12h),;C_{max};and;T_{max} between the two formulations (6.72%,;1.52%,;and;0.88, respectively). The least significant differences between the formulations at alpha=0.05 were less than 20%;(11.65%,;19.73%,;and;14.81%;for;AUC_{0-12h},;C_{max};and;T_{max}, respectively). The 90% confidence intervals for these parameters were also within pm20%;(-1.50{leq}{delta}{leq}15.00, -12.50{leq}{delta}{leq}15.50,;and;-9.64{leq}{delta]{leq}11.40{leq};for;;AUC_{0-12h} ,C_{max};and;T_{max}, respectively). In conclusion, the new generic product Lovaload^{TM} was proven to be bioequivalent with the reference drug.
|